Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
Want to see KZR full AI Analyst Report?
KZR Stock Chart & Stats
$7.33
-$0.28(-4.09%)
At close: 4:00 PM EST
$7.33
-$0.28(-4.09%)
Day’s Range― - ―
52-Week Range$3.53 - $7.55
Previous CloseN/A
Volume19.48K
Average Volume (3M)297.79K
Market Cap
$53.86M
Enterprise Value-$11.02M
Total Cash (Recent Filing)$66.23M
Total Debt (Recent Filing)$1.35M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.17
Shares Outstanding7,387,701
10 Day Avg. Volume813,550
30 Day Avg. Volume297,789
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit62.61
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$7.00Price Target Upside-4.50% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-4.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market OpportunityAnalyst highlights that autoimmune hepatitis lacks approved therapies, creating an attractive commercial opportunity if zetomipzomib achieves regulatory approval.
Regulatory ClarityAnalyst notes alignment with the FDA on key trial design elements such as treatment duration, safety monitoring, endpoints, and enrollment criteria, which supports a potential registrational path and increases partner interest.
ValuationAnalyst believes the current valuation reflects the company's development stage and the additional trials required to bring zetomipzomib to market, supporting limited downside relative to the firm's cash and liabilities.
Bears Say
Acquisition Valuation RiskAnalyst expresses uncertainty about whether the acquisition is primarily a cash consolidation play and notes that market pricing appears to reflect interest in the company's cash balance rather than the long-term value of zetomipzomib, which may limit upside for shareholders.
Operational UncertaintyAnalyst points out that the company is winding down operations and pursuing strategic alternatives, signaling operational downscaling and uncertainty about its viability as an independent developer.
Safety RiskAnalyst warns that serious adverse events in prior trials led to trial termination, creating significant safety and regulatory risk for future development of zetomipzomib.
Kezar Life Sciences News
KZR FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was $3.53 and its highest was $7.55 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Kezar Life Sciences Inc’s market cap is $53.86M.
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Aug 06, 2026 which is in 76 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on May 07, 2026. The company reported -$0.784 earnings per share for the quarter, beating the consensus estimate of -$1.03 by $0.246.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Overvalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 7,387,701 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -$0.784 in its last earnings report, beating expectations of -$1.03. Following the earnings report the stock price went down -0.271%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Currently, no hedge funds are holding shares in KZR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kezar Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.00 (-4.50% Downside)
$7.00 (-4.50% Downside)
Hedge Fund Trend
Decreased
By 25.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.05%
12-Months-Change
Fundamentals
Return on Equity
-58.35%
Trailing 12-Months
Asset Growth
-45.71%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
KZR Stock 12 Month Forecast
Average Price Target
$7.00
▼(-4.50% Downside)
Technical Analysis
Ownership Overview
― Insiders
11.67% Mutual Funds
43.30% Other Institutional Investors
40.83% Public Companies and
Individual Investors